Mission/Background :
FELIQS is a crossborder clinical-stage company, focused on developing the first oral treatment for retinopathy of prematurity(ROP), a leading cause of childhood blindness in extremely preterm neonates. Our lead candidate, FLQ-101, is ready to enroll patients in its Phase 1b/2a study in the US. We have obtained proof of concept in relevant animal studies and FDA has granted FELIQS orphan drug designation resulting in 7-year exclusivity and thus fast tracking the program to a commercial launch currently planned for 2027. FLQ-101 provides a de-risked pathway and could represent a first-in-class oral treatment for ROP which reduces neonatal hospital stay by 50% hence addressing approximately a $1.0 billion market potential.